Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients

Hepatology International

Volumn 9, Issue 3, 2015, Pages 431-437

  Devaki, Pardha ^a   Jencks, David ^b   Yee, Brittany E ^c   Nguyen, Mindie H ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Genotype 5; Hepatitis C; Peginterferon and ribavirin; Sustained virologic response

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ARTICLE; CLINICAL EFFECTIVENESS; EVIDENCE BASED PRACTICE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 5; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; META ANALYSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RECURRENCE RISK; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; RIBAVIRIN;

EID: 84931567386     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-015-9635-z     Document Type: Article

References (20)

1. WHO. Hepatitis C: Media Centre. World Health Organization. http://www.who.int/mediacentre/factsheets/fs164/en/. 28 Aug 2014
2. Francisco MAN, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012;55(S1):S10–S15
3. Papastergious VSL, Lisgos P, et al. Hepatitis C virus genotype 5: prospective evaluation of peginterferon/ribavirin treatment efficacy and predictive value of on-treatment virological responses for sustained virological response. Clin Gastroenterol 2014;48(2):160–165
4. Smuts HEKJ. Genotyping of hepatitis C virus in South Africa. J Clin Microbiol 1995;33:1679–1681
5. Wantuck JMAA, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014;39(2):137–147
6. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org
7. Abergel A, Achim A, Kain I, Lamblin G, Randl K, Nicolas C, et al. Efficacy of Interferon (Standard or Pegylated) Plus Ribavirin in Naive Patients with Hepatitis C Vitus Genotype 5. A French Multicenter Study. Hepatology 2011;54:817A
8. Antaki N, Bibert S, Kebbewar K, et al. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut 2012;61(11):1640–1641
9. Antaki N, Hermes A, Hadad M, et al. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J Viral Hepat 2008;15(5):383–386
10. Bonny C, Fontaine H, Poynard T, et al. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 2006;24(4):593–600
11. D’Heygere F, George C, Van Vlierberghe H, et al. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: a meta-analysis of two large prospective clinical trials. J Med Virol 2011;83(5):815–819
12. Karatapanis S, Tsoplou P, Papastergiou V, et al. Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island. J Med Virol 2012;84(2):223–228
13. Legrand-Abravanel F, Sandres-Saune K, Barange K, et al. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis 2004;189(8):1397–1400
14. Mauss S, Berger F, Vogel M, et al. Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Z Gastroenterol 2012;50(5):441–444
15. Papastergiou V, Skorda L, Lisgos P, et al. Hepatitis C virus genotype 5: prospective evaluation of peginterferon/ribavirin treatment efficacy and predictive value of on-treatment virological responses for sustained virological response. J Clin Gastroenterol 2014;48(2):160–165
16. Sonderup MW, Abuelhassan W, Spearman CW. IL28B polymorphisms are not predictive in hepatitis C genotype 5 infected with South African patients. Hepatology 2012;56:1029A
17. Sofia MJ, Bao D, Chang W, et al. Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010;53(19):7202–7218
18. Global Health Initiative Strategy 2011–2016: South Africa; 2011. (Accessed 11 Nov 2014). http://www.ghi.gov/whereWeWork/docs/SouthAfricaStrategy.pdf
19. World Health Organization: Bridging the gap in South Africa; 2014. Retrived from http://www.who.int/bulletin/volumes/88/11/10-021110/en/
20. World Health Organization: South Africa; 2012. (Accessed 11 Nov 2014). http://www.who.int/countries/zaf/en/